$7.67 -0.23 (-2.91%)
11/6/2009 4:00 PM

The Medicines Company (MDCO)

CAPS Rating: 3 out of 5

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

Current Price $7.67 Mkt Cap $404.56M
Open $7.81 P/E Ratio 17.95
Prev. Close $7.90 Div. (Yield) N/A (N/A)
Daily Range $7.58 - $7.86 Volume 388,712
52-Wk Range $6.15 - $17.54 Avg. Daily Vol. 437,000

MDCO News and Commentary

Caps

How do you think MDCO will perform vs the S&P 500?

Add Stock to Watchlist

All Members

83 Outperform
14 Underperform
 

All-Star Members

21 Outperform
2 Underperform
 

Wall Street

3 Outperform
2 Underperform
 

Top MDCO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

popsstocs (< 20)
Submitted September 08, 2007

I have made some good profits off this CO.I guess it makes all that money from selling all those expensive medications,but what ever,It does me good and I played it again,and its already on its way to do ole pops right again.

0 Comments | Reply | Report this Post

agard43 (< 20)
Submitted March 23, 2007

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

0 Comments | Reply | Report this Post
MDCO VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about MDCO.

Recs

0
Member Avatar Magnet0 (73.22) Submitted: 5/13/2009 5:50:39 PM : Outperform Start Price: $7.22 MDCO Score: -15.77

quality company, took a fatty nose dive

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar TSIF (98.51) Submitted: 5/12/2009 2:46:39 PM : Outperform Start Price: $11.14 MDCO Score: -50.47

The Medicine Company, winning name, great pitch, "cost effective acute care"!. How could it lose! Overall for a pharmaceutical company Medicines has a decent and increasing revenue stream from Angiomax and several other products. From the company profile Angiomax is " an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty". Wow, I don't know what it means, but it must be good! Yes, patents are short, which appears to be keeping the price down, but it has other drugs in the "blood arena" and we all need healthy blood! They will need to watch their backs, but no debt, cash flow, well respected products and a good distribution system and I'd rather have my money in a company like this than an auto parts or a bank, especially if I need to go to the hospital to have my thromin fixed.

Report this Post 1 Comment | Reply | Permalink

Recs

0
Member Avatar zzlangerhans (99.36) Submitted: 2/20/2009 1:07:40 PM : Outperform Start Price: $12.61 MDCO Score: -82.47

It's not clear to me why Medicines has fallen so far despite a relatively stable financial picture. Angiomax revenues have been increasing and generics will not be available before 2010 at the earliest. That gives Medicines time to grow Cleviprex revenues and develop their pipeline. I'm not really a bull here but this company has the tools to survive and will likely be one to rebound in the short term when the market stabilizes, given no major negative catalysts.

Report this Post 0 Comments | Reply | Permalink
View All 11 Pitches »

Leaderboard

Find the members with the highest scoring picks in MDCO.

Score Leader

lwc123

lwc123 (76.41) Score: +73.52

The Score Leader is the member with the highest score across all their picks in MDCO.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
lwc123 76.41 1/8/2009 Underperform 3Y $16.18 -52.60% +20.92% +73.52
naygoo 56.20 12/11/2006 Underperform 3W $30.96 -75.23% -19.84% +55.39 1 Comment
amikkelson < 20 9/26/2006 Underperform 1Y $22.40 -65.76% -14.17% +51.59
agard43 < 20 3/23/2007 Underperform 3M $25.17 -69.53% -20.95% +48.57 1 Comment
eddie911 21.36 6/30/2008 Underperform 3W $19.19 -60.03% -13.59% +46.44
ToeInsider 32.31 3/11/2008 Underperform NS $17.19 -55.38% -14.59% +40.79
rrrobz 86.60 5/15/2008 Underperform 3W $19.64 -60.95% -21.31% +39.64
mdowx < 20 5/22/2007 Underperform 1Y $20.28 -62.18% -25.83% +36.35
puck234 44.02 10/4/2007 Underperform 3M $18.97 -59.57% -27.17% +32.40
stockgripes 98.35 9/2/2009 Underperform 5Y $10.03 -23.53% +7.42% +30.95
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackWedbush < 20 9/15/2009 Underperform NS $11.08 -30.78% +2.08% +32.85
TrackWedbush < 20 5/13/2009 Outperform NS $7.31 +51.57% +19.68% +31.90 9/15/2009 @ $11.08
TrackCitigroup 21.22 2/14/2008 Outperform NS $21.23 -63.87% -18.48% -45.40
TrackUBS 86.41 10/2/2007 Outperform NS $19.50 -59.28% -36.13% -23.15 7/30/2009 @ $7.94
TrackJMP < 20 4/30/2007 Outperform NS $23.13 -66.84% -24.32% -42.52
TrackRBCCapMkts 81.74 4/30/2007 Underperform NS $23.16 -12.09% +3.47% +15.56 7/20/2007 @ $20.36
TrackUBS 86.41 1/16/2007 Underperform NS $32.83 -40.60% +8.00% +48.60 10/2/2007 @ $19.50
TrackRBCCapMkts 81.74 10/26/2006 Outperform NS $24.65 -5.88% +7.78% -13.66 4/30/2007 @ $23.20
TrackBroadpoint.AmTech 73.02 10/26/2006 Outperform NS $24.65 -68.88% -18.02% -50.86
TrackJimCramer < 20 3/13/2006 Underperform 3W $21.40 -64.16% -10.79% +53.37

Featured Broker Partners